Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 16th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Pembrolizumab Plus Trastuzumab/Chemo Significantly Improves OS in Gastric/GEJ Cancer
Frontline treatment with pembrolizumab plus trastuzumab/chemotherapy significantly and meaningfully improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.
Adverse Effect Management for Immunotherapies in Advanced Endometrial Cancer
May 13th 2024Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology nurses and for patients with advanced endometrial cancer who are treated with immunotherapies.
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.